World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
139
Citations
77854
World Ranking
1747
National Ranking
998

Overview

Farhad Ravandi is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on hematology within the broader field of medicine, contributing extensively to acute myeloid leukemia and related hematological malignancies.

Their recent research publications have appeared in several well-regarded journals. Notable papers include:

  • "Acute myeloid leukemia: current progress and future directions," Blood Cancer Journal, 2021
  • "2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party," Blood, 2021
  • "Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission," New England Journal of Medicine, 2020
  • "Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges," Cancer Discovery, 2020
  • "Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics," Nature Communications, 2020

These publications highlight a focus on acute myeloid leukemia, including molecular mechanisms, minimal residual disease assessment, and novel therapeutic approaches.

Frequent collaborators in their research include:

  • Hagop M. Kantarjian
  • Tapan M. Kadia
  • Nicholas J. Short
  • Elias Jabbour
  • Courtney D. DiNardo

Their work has been published extensively in several core scientific venues, such as:

  • Blood
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Cancer
  • Blood Advances

Farhad Ravandi's research fields cover several interconnected specialties, including hematology, genetics, molecular biology, public health, and oncology. Their work touches on topics with a strong clinical and translational focus, such as:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Multiple Myeloma Research and Treatments

This body of work represents a commitment to expanding understanding of blood cancers and developing improved treatment modalities. Through collaboration with prominent coauthors and contributions across multiple high-impact journals, Farhad Ravandi has become an active figure within the research community focusing on hematologic malignancies.

Best Publications

  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

    Hagop Kantarjian;Jean-Pierre J. Issa;Craig S. Rosenfeld M.D.;John M. Bennett

  • Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

    Hagop Kantarjian;Susan O'Brien;Farhad Ravandi;Jorge Cortes

  • Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

    Margaret R. O'Donnell;Martin S. Tallman;Camille N. Abboud;Jessica K. Altman

  • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

    Andres O. Soriano;Hui Yang;Stefan Faderl;Zeev Estrov

  • Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    Miguel A. Sanz;Miguel A. Sanz;Pierre Fenaux;Martin S. Tallman;Elihu H. Estey

  • Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

    Michael Heuser;Sylvie D Freeman;Gert J Ossenkoppele;Francesco Buccisano

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

    Farhad Ravandi;Eli Estey;Dan Jones;Stefan Faderl

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

    Hagop M. Kantarjian;Susan OBrien;Elias Joseph Jabbour;Guillermo Garcia-Manero

  • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

    Hagop M. Kantarjian;Farhad Ravandi;Susan OBrien;Jorge Cortes

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing Medicine in the USA is highly competitive, there are multiple alternative online degrees and career routes in healthcare that offer rewarding opportunities. Nursing is one of the most popular fields, and finding affordable education options is crucial for many students.

For those interested in advanced practice, there are cheap np programs that allow registered nurses to become nurse practitioners with flexible, cost-effective study options. If you’re already a registered nurse seeking to advance your educational credentials, you may want to explore what is the cheapest rn to bsn program online to maximize value and convenience.

Students can also consider the cheapest rn to bsn online programs to bridge the gap between an associate and bachelor's degree. For those pursuing leadership or academic roles within nursing, online doctoral studies are becoming more accessible, and information on affordable phd in nursing pathways can help open the door to research and higher education positions.

These online degrees offer flexibility and cost savings, making healthcare careers accessible for a wider range of students.

Best Scientists Citing Farhad Ravandi

Trending Scientists

Recently Published Articles